RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eagle Pharmaceuticals Stock

Eagle Pharmaceuticals P/S 2024

Eagle Pharmaceuticals P/S

0.23

Ticker

EGRX

ISIN

US2697961082

WKN

A1XEDS

As of Oct 25, 2024, Eagle Pharmaceuticals's P/S ratio stood at 0.23, a -77.67% change from the 1.03 P/S ratio recorded in the previous year.

The Eagle Pharmaceuticals P/S history

Eagle Pharmaceuticals Aktienanalyse

What does Eagle Pharmaceuticals do?

Eagle Pharmaceuticals Inc was founded in 2007 and is based in New Jersey, USA. The company operates in the field of development and marketing of pharmaceutical products. History Eagle Pharmaceuticals was founded by Scott Tarriff, an experienced entrepreneur and expert in the fields of pharmacy and biotechnology. The goal was to create a company focused on developing generic drugs with improved effectiveness. Eagle Pharmaceuticals started with two products - Argatroban and Ryanodex. Argatroban is an anticoagulant used in the treatment of thrombosis. Ryanodex is a muscle relaxant for patients suffering from malignant hyperthermia. Business model Eagle Pharmaceuticals has a unique business model that sets it apart from other pharmaceutical companies. They focus on developing generic drugs with improved effectiveness instead of entirely new drugs. The company also focuses on licensing technologies rather than spending money on research and development. The company works closely with doctors and hospitals to ensure that their products meet the needs of patients. Divisions Eagle Pharmaceuticals is divided into two business segments - branded and generic products. Branded products: The company develops and distributes generic products with improved effectiveness. These include products such as Ryanodex, Bendeka, Belrapzo, and Pemetrexed. Generic products: The company has a wide range of generic products used in the areas of anticoagulants, oncology, and pain management. These include products such as Argatroban, Docetaxel, Phenylephrine HCl, and Bivalirudin. Products Argatroban: An anticoagulant used in patients with thrombosis or thromboembolic events. Ryanodex: A muscle relaxant used in patients suffering from malignant hyperthermia. Bendeka: A medication for leukemia used in combination with other chemotherapies. Belrapzo: A medication for certain types of cancer used in combination with other chemotherapies. Pemetrexed: A medication for various cancer diseases, such as lung and breast cancer. Docetaxel: A medication for various cancer diseases, such as breast cancer, lung cancer, and prostate cancer. Phenylephrine HCl: A medication for high blood pressure and bronchodilation. Bivalirudin: An anticoagulant used in patients undergoing angioplasty or coronary bypass surgery. In summary, Eagle Pharmaceuticals is an innovative pharmaceutical company that focuses on developing drugs with improved effectiveness. The company has a wide range of products in the areas of oncology, pain management, and anticoagulants. It works closely with doctors and hospitals to ensure that its products meet the needs of patients. Eagle Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Eagle Pharmaceuticals's P/S Ratio

Eagle Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Eagle Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Eagle Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Eagle Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Eagle Pharmaceuticals stock

What is the price-to-earnings ratio of Eagle Pharmaceuticals?

The price-earnings ratio of Eagle Pharmaceuticals is currently 0.23.

How has the price-earnings ratio of Eagle Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Eagle Pharmaceuticals has increased by -77.67% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Eagle Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Eagle Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Eagle Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Eagle Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Eagle Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Eagle Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Eagle Pharmaceuticals?

Some factors that influence the price-earnings ratio of Eagle Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Eagle Pharmaceuticals pay?

Over the past 12 months, Eagle Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eagle Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eagle Pharmaceuticals?

The current dividend yield of Eagle Pharmaceuticals is .

When does Eagle Pharmaceuticals pay dividends?

Eagle Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eagle Pharmaceuticals?

Eagle Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eagle Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eagle Pharmaceuticals located?

Eagle Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eagle Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eagle Pharmaceuticals from 10/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.

When did Eagle Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/25/2024.

What was the dividend of Eagle Pharmaceuticals in the year 2023?

In the year 2023, Eagle Pharmaceuticals distributed 0 USD as dividends.

In which currency does Eagle Pharmaceuticals pay out the dividend?

The dividends of Eagle Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Eagle Pharmaceuticals

Our stock analysis for Eagle Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eagle Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.